This Article Figures Only Full Text Full Text (PDF) View CVN Genuine Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Pitt, B. Articles by Raichlen, J. S. Search for Related Content PubMed Articles by Pitt, B. Articles by Raichlen, J. S. Related Collections Related Articles

CLINICAL RESEARCH: ACUTE CORONARY SYNDROME

Lipid Levels After Acute Coronary Syndromes

Bertram Pitt, MD, FACC^_*,_*, Joseph Loscalzo, MD, PhD, FACC, Joseph Yas, PhD and Joel S. Raichlen, MD, FACC

^_* Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan
Department of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
AstraZeneca LP, Wilmington, Delaware.

Manuscript received August 24, 2007; revised manuscript received November 1, 2007, accepted November 14, 2007.

^_* Reprint requests and correspondence: Dr. Bertram Pitt, 1500 East Medical Center Drive, 3910 Taubman Center, Ann Arbor, Michigan 48109-0366. (Email: bpitt{at}med.umich.edu).

A preliminary version of this analysis was presented as a poster at the 55th Annual Scientific Session of the American College of Cardiology, Atlanta, Georgia, March 11 to 14, 2006.

Objectives: This analysis from the LUNAR (Limiting UNdertreatment of lipids in ACS with Rosuvastatin) study assessed lipid changes 1 to 4 days after onset of acute coronary syndromes (ACS), before initiation of study treatment.

Background: Early studies indicated that cholesterol levels decrease significantly after ACS. However, most studies were small or did not measure low-density lipoprotein cholesterol (LDL-C) directly, and many used nonfasting or retrospective data. More recent studies suggest less pronounced changes in cholesterol levels after ACS.

Methods: The LUNAR trial is a prospective, multicenter, randomized, open-label study in adults hospitalized for acute ST-segment elevation myocardial infarction (STEMI), non-STEMI, or unstable angina (UA). Blood samples were taken at median times after onset of ACS symptoms of 26 h (Day 1, fasting or nonfasting sample), 43 h (Day 2, fasting sample), and 84 h (Day 4, fasting sample) for direct measurement of serum lipid levels before study treatments were started.

Results: Of 507 patients available for analysis, 212 were admitted for STEMI, 176 for non-STEMI, and 119 for UA. The LDL-C levels decreased in the 24 h after admission (from 136.2 to 133.5 mg/dl), followed by an increase over the subsequent 2 days (to 141.8 mg/dl). These changes did not seem to be clinically meaningful. Similar changes were observed for total cholesterol and smaller changes for high-density lipoprotein cholesterol; fasting triglyceride levels did not change.

Conclusions: Mean lipid levels vary relatively little in the 4 days after an ACS and can be used to guide selection of lipid-lowering medication. (LUNAR Phase IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes; NCT00214630 [ClinicalTrials.gov] )

Abbreviations and Acronyms   ACS = acute coronary syndrome(s)   HDL-C = high-density lipoprotein cholesterol   IQR = interquartile range   LDL-C = low-density lipoprotein cholesterol   STEMI = ST-segment elevation myocardial infarction   TC = total cholesterol   TG = triglyceride(s)   UA = unstable angina

Related Articles

Lipid Levels in the Post-Acute Coronary Syndrome Setting: Destabilizing Another Myth?

Michael Miller
J. Am. Coll. Cardiol. 2008 51: 1446-1447. [Full Text] [PDF]

This article has been cited by other articles:

				J. L. Mega, D. A. Morrow, A. Brown, C. P. Cannon, and M. S. Sabatine Identification of Genetic Variants Associated With Response to Statin Therapy Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1310 - 1315. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				Authors/Task Force Members, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: Eur. Heart J., December 1, 2008; 29(23): 2909 - 2945. [Full Text] [PDF]

				Lipid Levels in Acute Coronary Syndrome Journal Watch (General), May 13, 2008; 2008(513): 3 - 3. [Full Text]

				M. Miller Lipid Levels in the Post-Acute Coronary Syndrome Setting: Destabilizing Another Myth? J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1446 - 1447. [Full Text] [PDF]